Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 17 March 2000:
Vol. 287. no. 5460, pp. 2020 - 2022
DOI: 10.1126/science.287.5460.2020
Prev | Table of Contents | Next

Reports

Reversal of AntipsychoticInduced Working Memory Deficits by Short-Term Dopamine D1 Receptor Stimulation

Stacy A. Castner, Graham V. Williams, Patricia S. Goldman-Rakic *

Chronic blockade of dopamine D2 receptors, a common mechanism of action for antipsychotic drugs, down-regulates D1 receptors in the prefrontal cortex and, as shown here, produces severe impairments in working memory. These deficits were reversed in monkeys by short-term coadministration of a D1 agonist, ABT 431, and this improvement was sustained for more than a year after cessation of D1 treatment. These findings indicate that pharmacological modulation of the D1 signaling pathway can produce long-lasting changes in functional circuits underlying working memory. Resetting this pathway by brief exposure to the agonist may provide a valuable strategy for therapeutic intervention in schizophrenia and other dopamine dysfunctional states.

Section of Neurobiology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA.
*   To whom correspondence should be addressed. E-mail: Patricia.Goldman-Rakic{at}yale.edu

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Quantitative Analysis of the Expression of Dopamine D1 and D2 Receptors in Pyramidal and GABAergic Neurons of the Rat Prefrontal Cortex.
N. Santana, G. Mengod, and F. Artigas (2009)
Cereb Cortex 19, 849-860
   Abstract »    Full Text »    PDF »
Messing Up with Traffic: Different Effects of Antipsychotic Agents on Glutamate Receptor Complexes in Vivo.
T. Del'guidice and J.-M. Beaulieu (2008)
Mol. Pharmacol. 73, 1339-1342
   Abstract »    Full Text »    PDF »
Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia.
J. A. Gray and B. L. Roth (2007)
Schizophr Bull 33, 1100-1119
   Abstract »    Full Text »    PDF »
Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia.
R. W. Buchanan, R. Freedman, D. C. Javitt, A. Abi-Dargham, and J. A. Lieberman (2007)
Schizophr Bull 33, 1120-1130
   Abstract »    Full Text »    PDF »
Plasticity of the Primate Prefrontal Cortex.
S. Kuboshima-Amemori and T. Sawaguchi (2007)
Neuroscientist 13, 229-240
   Abstract »    PDF »
Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial.
R. S. E. Keefe, R. M. Bilder, S. M. Davis, P. D. Harvey, B. W. Palmer, J. M. Gold, H. Y. Meltzer, M. F. Green, G. Capuano, T. S. Stroup, et al. (2007)
Arch Gen Psychiatry 64, 633-647
   Abstract »    Full Text »    PDF »
Adverse effects of risperidone on spatial working memory in first-episode schizophrenia..
J. L. Reilly, M. S. H. Harris, M. S. Keshavan, and J. A. Sweeney (2006)
Arch Gen Psychiatry 63, 1189-1197
   Abstract »    Full Text »    PDF »
Where Do You Think You Are Going? The NMDA-D1 Receptor Trap.
C. Cepeda and M. S. Levine (2006)
Sci. STKE 2006, pe20
   Abstract »    Full Text »    PDF »
Reversal of brain injury-induced prefrontal glutamic acid decarboxylase expression and working memory deficits by D1 receptor antagonism..
N. Kobori and P. K. Dash (2006)
J. Neurosci. 26, 4236-4246
   Abstract »    Full Text »    PDF »
Targeting Prefrontal Cortical Dopamine D1 and N-Methyl-D-Aspartate Receptor Interactions in Schizophrenia Treatment.
C. R. Yang and L. Chen (2005)
Neuroscientist 11, 452-470
   Abstract »    PDF »
Synthesizing Schizophrenia: A Bottom-Up, Symptomatic Approach.
T. W Robbins (2005)
Schizophr Bull 31, 854-864
   Abstract »    Full Text »    PDF »
Predicting Drug Efficacy for Cognitive Deficits in Schizophrenia.
J. J Hagan and D. N C Jones (2005)
Schizophr Bull 31, 830-853
   Abstract »    Full Text »    PDF »
The Effects of Clozapine and Risperidone on Spatial Working Memory in Schizophrenia.
S. R. McGurk, C. Carter, R. Goldman, M. F. Green, S. R. Marder, H. Xie, N. R. Schooler, and J. M. Kane (2005)
Am J Psychiatry 162, 1013-1016
   Abstract »    Full Text »    PDF »
A role for prefrontal calcium-sensitive protein phosphatase and kinase activities in working memory.
J. D. Runyan, A. N. Moore, and P. K. Dash (2005)
Learn. Mem. 12, 103-110
   Abstract »    Full Text »    PDF »
Sustained Extracellular Signal-Regulated Kinase 1/2 Phosphorylation in Neonate 6-Hydroxydopamine-Lesioned Rats after Repeated D1-Dopamine Receptor Agonist Administration: Implications for NMDA Receptor Involvement.
S. T. Papadeas, B. L. Blake, D. J. Knapp, and G. R. Breese (2004)
J. Neurosci. 24, 5863-5876
   Abstract »    Full Text »    PDF »
Microdomains for Dopamine Volume Neurotransmission in Primate Prefrontal Cortex.
C. D. Paspalas and P. S. Goldman-Rakic (2004)
J. Neurosci. 24, 5292-5300
   Abstract »    Full Text »    PDF »
Comparative Effect of Atypical and Conventional Antipsychotic Drugs on Neurocognition in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Low Doses of Haloperidol.
R. S.E. Keefe, L. J. Seidman, B. K. Christensen, R. M. Hamer, T. Sharma, M. M. Sitskoorn, R. R.J. Lewine, D. A. Yurgelun-Todd, R. C. Gur, M. Tohen, et al. (2004)
Am J Psychiatry 161, 985-995
   Abstract »    Full Text »    PDF »
Enhancement of Working Memory in Aged Monkeys by a Sensitizing Regimen of Dopamine D1 Receptor Stimulation.
S. A. Castner and P. S. Goldman-Rakic (2004)
J. Neurosci. 24, 1446-1450
   Abstract »    Full Text »    PDF »
Regulation of Dopamine D1 Receptor Function by Physical Interaction with the NMDA Receptors.
L. Pei, F. J. S. Lee, A. Moszczynska, B. Vukusic, and F. Liu (2004)
J. Neurosci. 24, 1149-1158
   Abstract »    Full Text »    PDF »
Schizophrenia.
R. Freedman (2003)
N. Engl. J. Med. 349, 1738-1749
   Full Text »    PDF »
Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia.
A. Abi-Dargham and H. Moore (2003)
Neuroscientist 9, 404-416
   Abstract »    PDF »
Effects of Typical, Atypical, and No Antipsychotic Drugs on Visual Contrast Detection in Schizophrenia.
Y. Chen, D. L. Levy, S. Sheremata, K. Nakayama, S. Matthysse, and P. S. Holzman (2003)
Am J Psychiatry 160, 1795-1801
   Abstract »    Full Text »    PDF »
Up-regulation of the D1 Dopamine Receptor-Interacting Protein, Calcyon, in Patients With Schizophrenia.
P. O. Koh, C. Bergson, A. S. Undie, P. S. Goldman-Rakic, and M. S. Lidow (2003)
Arch Gen Psychiatry 60, 311-319
   Abstract »    Full Text »    PDF »
Up-regulation of the D1 Dopamine Receptor-Interacting Protein, Calcyon, in Patients With Schizophrenia.
P. O. Koh, C. Bergson, A. S. Undie, P. S. Goldman-Rakic, and M. S. Lidow (2003)
Arch Gen Psychiatry 60, 311-319
   Abstract »    Full Text »
The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans.
C. F. Bartholomeusz, G. Box, C. Van Rooy, and P. J. Nathan (2003)
J Psychopharmacol 17, 9-15
   Abstract »    PDF »
Mice Lacking Dopamine D2 and D3 Receptors Have Spatial Working Memory Deficits.
S. B. Glickstein, P. R. Hof, and C. Schmauss (2002)
J. Neurosci. 22, 5619-5629
   Abstract »    Full Text »    PDF »
PET Study of D1 Dopamine Receptor Binding in Neuroleptic-Naive Patients With Schizophrenia.
P. Karlsson, L. Farde, C. Halldin, and G. Sedvall (2002)
Am J Psychiatry 159, 761-767
   Abstract »    Full Text »    PDF »
Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia.
A. Abi-Dargham, O. Mawlawi, I. Lombardo, R. Gil, D. Martinez, Y. Huang, D.-R. Hwang, J. Keilp, L. Kochan, R. Van Heertum, et al. (2002)
J. Neurosci. 22, 3708-3719
   Abstract »    Full Text »    PDF »
The Physiological Role of 5-HT2A Receptors in Working Memory.
G. V. Williams, S. G. Rao, and P. S. Goldman-Rakic (2002)
J. Neurosci. 22, 2843-2854
   Abstract »    Full Text »    PDF »
Visual Perceptual and Working Memory Impairments in Schizophrenia.
C. Tek, J. Gold, T. Blaxton, C. Wilk, R. P. McMahon, and R. W. Buchanan (2002)
Arch Gen Psychiatry 59, 146-153
   Abstract »    Full Text »    PDF »
Enhanced or Impaired Cognitive Function in Parkinson's Disease as a Function of Dopaminergic Medication and Task Demands.
R. Cools, R. A. Barker, B. J. Sahakian, and T. W. Robbins (2001)
Cereb Cortex 11, 1136-1143
   Abstract »    Full Text »    PDF »
The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?.
R. A. Bantick, J. F. W. Deakin, and P. M. Grasby (2001)
J Psychopharmacol 15, 37-46
   Abstract »    PDF »
A Single Dose of Methamphetamine Leads to a Long Term Reversal of the Blunted Dopamine D1 Receptor-mediated Neocortical c-fos Responses in Mice Deficient for D2 and D3 Receptors.
C. Schmauss (2000)
J. Biol. Chem. 275, 38944-38948
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)